Listing 11.14 in 2026: Peripheral Neuropathy SSDI

By Anthony Albert, Benefits Research Director, Disability Exchange. Published June 23, 2026. Disability Exchange is privately owned and not affiliated with the SSA.

If you filed an SSDI or SSI claim because diabetic peripheral neuropathy, chemo induced neuropathy, CIDP, Guillain Barre residuals, Charcot Marie Tooth, or another nerve disease wrecked your feet, your hands, or your balance, Social Security evaluates you under Listing 11.14 of the Blue Book. That listing has not changed in text since the 2016 neurological revision, but the way DDS examiners read it in 2026 is tighter than it was even three years ago. The motor disorganization standard pulls in directly from section 11.00D. The marked physical plus marked mental path pulls in from section 11.00G. Most files lose at Step 3 not because the neuropathy is mild, but because the evidence does not line up with the exact language Social Security uses.

This page lays out the listing text, defines every term the way SSA defines it, walks through the two evidence paths, gives you the workup most files are missing, and shows two worked examples. Then it covers what wins on residual functional capacity when the listing does not quite hit.

The Listing 11.14 Text Read Word By Word

Listing 11.14 is short. It reads: peripheral neuropathy, characterized by A or B. Paragraph A is disorganization of motor function in two extremities, see 11.00D1, resulting in an extreme limitation, see 11.00D2, in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities. Paragraph B is marked limitation, see 11.00G2, in physical functioning, see 11.00G3a, and in one of the four areas of mental functioning, see 11.00G3b. The four mental areas are understanding, remembering, or applying information, interacting with others, concentrating, persisting, or maintaining pace, and adapting or managing oneself.

That is the whole listing. The fight is inside the cross referenced sections. SSA examiners do not approve claims off the text of 11.14 alone. They approve off 11.00D, 11.00G, and the medical documentation behind them.

Paragraph A: Motor Disorganization in Two Extremities

Section 11.00D1 defines disorganization of motor function as interference with movement of two extremities because of the neurological disorder. Two extremities means both lower, both upper, or one upper and one lower. The interference does not have to be the same on both sides. A claimant with severe right hand weakness and severe left foot drop satisfies the two extremity requirement. What examiners look for is documented and persistent interference, not a one time exam finding.

Section 11.00D2 sets the extreme limitation bar. You meet the extreme threshold if the interference rises to an inability to stand up from a seated position without help from another person or without a walker, bilateral crutches, or bilateral canes. The same bar applies to balance while standing or walking. For the upper extremities, the bar is an inability to use both upper extremities to the extent needed to independently initiate, sustain, and complete work related activities involving fine and gross movements. That means pinching, grasping, gripping, turning, reaching, lifting, carrying, pushing, and pulling.

Note the structure. Extreme limitation in one area is enough. A claimant who cannot stand from a chair without a walker meets the bar even if balance and upper extremity use are only moderately affected. The motor disorganization itself has to involve two extremities, but the extreme limitation it produces only has to hit one of the three functional outcomes.

Paragraph B: Marked Physical Plus Marked Mental

Paragraph B is the path most diabetic and chemo induced neuropathy claims actually win on. The motor disorganization in paragraph A is a high bar. Paragraph B settles for marked rather than extreme in physical functioning, but it adds a marked mental functioning requirement on top.

Section 11.00G2 defines marked limitation as functioning at a level that seriously limits your ability to independently initiate, sustain, and complete the relevant activity. SSA uses a 5 point scale. None, mild, moderate, marked, extreme. Marked is the second highest. It is more than moderate but less than extreme.

Section 11.00G3a, the physical functioning leg, gives a non exhaustive list of activities. Standing from a seated position. Balance while standing or walking. Use of upper extremities. Plus body functions that support motor abilities such as vision, breathing, and swallowing. Marked limitation in physical functioning under 11.00G can be shown by needing a cane (not bilateral, because bilateral would already put you in extreme), needing frequent rest breaks during walking, dropping objects when reaching, or being unable to manipulate small items like buttons or coins.

Section 11.00G3b, the mental functioning leg, applies four areas borrowed from the 12.00 mental disorder framework. Understanding, remembering, or applying information. Interacting with others. Concentrating, persisting, or maintaining pace. Adapting or managing oneself. For paragraph B you only need marked limitation in one of those four. The mental piece has to be caused or significantly worsened by the neurological disorder itself. Chronic neuropathic pain that disrupts sleep and concentration counts. Medication side effects from gabapentin, pregabalin, duloxetine, amitriptyline, or tramadol count when documented. A separate untreated mental impairment does not satisfy the 11.00G mental leg unless it is medically linked back to the neuropathy.

The Diagnostic Evidence SSA Actually Wants

SSA requires objective medical evidence to establish peripheral neuropathy as a medically determinable impairment. Symptoms alone are not enough. The workup that wins these files usually includes three buckets.

First bucket. Nerve conduction studies and electromyography. Nerve conduction studies show slowing of conduction velocity, prolonged distal latencies, and reduced amplitudes consistent with demyelinating or axonal damage. EMG shows denervation, fibrillations, positive sharp waves, and reduced motor unit recruitment. For diabetic distal symmetric polyneuropathy the pattern is length dependent, axonal, sensorimotor, starting in the toes. For CIDP the pattern is demyelinating with conduction block. For Guillain Barre residuals the early acute EMG findings persist on follow up studies.

Second bucket. Lab confirmation of the underlying cause. Diabetic neuropathy needs HbA1c, fasting glucose, or oral glucose tolerance test results showing diabetes or prediabetes. Alcoholic neuropathy needs a treatment record showing alcohol use disorder and B12 plus thiamine deficiency. CIDP needs cerebrospinal fluid showing albuminocytologic dissociation. Vasculitic neuropathy needs sural nerve biopsy and ANCA testing. Chemo induced neuropathy needs the oncology record showing the offending drug (vincristine, oxaliplatin, paclitaxel, bortezomib, cisplatin, carboplatin) and dose received.

Third bucket. Functional documentation. This is where files most often fall short. The physician note needs to describe what the claimant can and cannot do. How far can the claimant walk. How long can the claimant stand. How much can the claimant carry. Can the claimant manipulate small objects. Are there frequent falls. Does the claimant use an assistive device. The Medical Source Statement form HA-1151 is the right vehicle. SSA examiners weight these by source acceptability and by detail under 20 CFR 404.1520c. A neurologist with longitudinal records carries more weight than a one time consultative examiner.

Diabetic Peripheral Neuropathy: The Largest Subset

Diabetic peripheral neuropathy hits up to 50 percent of people with type 1 or type 2 diabetes according to large population studies cited by Nature Reviews Neurology in 2024. That makes it the single largest subset under Listing 11.14. SSA removed diabetes itself from the Blue Book in 2011, so the diabetes diagnosis no longer triggers a listing. The neuropathy does.

For DDS examiners to approve a diabetic neuropathy file under 11.14, the record usually needs HbA1c documenting poor or moderate control, nerve conduction studies confirming length dependent sensorimotor neuropathy, and functional notes showing falls, gait instability, or hand dysfunction. A 10 gram monofilament test failure on standard sites supports loss of protective sensation but does not by itself meet the motor disorganization standard. Vibration testing with a 128 Hz tuning fork supports large fiber dysfunction.

If the lower extremities are affected but the upper extremities are not, paragraph A still works if the foot drop, balance loss, or gait disturbance is severe enough that the claimant cannot stand from a chair without a walker or bilateral support. Bilateral severe lower extremity neuropathy with falls and a walker prescription will usually meet paragraph A on lower extremities alone, because both legs count as the two extremities required.

Chemo Induced Peripheral Neuropathy

Chemo induced peripheral neuropathy (CIPN) has unique features SSA examiners now recognize more often than they did five years ago. The pattern is dose dependent and platinum or taxane mediated. Symptoms often start during chemo and persist for months or years after the last dose. Oxaliplatin causes acute and chronic neuropathy. Paclitaxel and docetaxel cause sensorimotor distal axonal damage. Bortezomib causes small fiber loss with severe burning pain. Vincristine causes motor predominant neuropathy with foot drop.

The evidence chain SSA wants is oncology records showing the drug and total dose, follow up neurology workup with NCS, and a functional statement. The 12 month duration requirement is satisfied if the neuropathy lasts past the 12 month mark from the last chemo dose. Some claimants meet paragraph B by combining marked physical functioning loss (cannot use hands for fine manipulation, cannot walk more than 200 feet) with marked mental from chronic neuropathic pain plus opioid or anticonvulsant side effects.

CIDP, GBS, CMT, Vasculitic, and Inflammatory Neuropathies

Chronic inflammatory demyelinating polyneuropathy (CIDP) is treatment responsive in many cases but a substantial subset of claimants have residual weakness and gait disturbance even with IVIG, plasma exchange, rituximab, or efgartigimod. The NCS findings of demyelination with conduction block plus CSF protein elevation usually establish the impairment. Functional residuals carry the listing analysis.

Guillain Barre residuals show up at the 6 to 12 month post acute mark. SSA cannot evaluate during the 3 to 6 month acute phase because the prognosis is unclear. After the 12 month durational window closes with persistent weakness, the same 11.14 analysis applies.

Charcot Marie Tooth disease, the most common inherited neuropathy, has its own pattern. Type 1A (PMP22 duplication) is the most common subtype. CMT progresses slowly and many claimants reach paragraph A motor disorganization in their 40s or 50s with severe foot drop, intrinsic hand muscle wasting, and assistive device dependence. Genetic testing supports the diagnosis. NCS shows uniformly slowed conduction velocities.

Vasculitic neuropathy is rarer but more aggressive. It usually presents as mononeuritis multiplex. Sural nerve biopsy showing necrotizing vasculitis is diagnostic. These claimants often meet paragraph A early in the disease course.

Worked Example One: Massachusetts Diabetic Neuropathy

Worked Example Two: Texas Chemo Induced Neuropathy

If The Listing Does Not Hit: RFC Backup

When paragraph A and paragraph B both fall short, the claim still has a path through Steps 4 and 5 of the sequential evaluation under 20 CFR 404.1520. The Residual Functional Capacity assessment carries the file at that point. Under SSR 96-9p the erosion of the sedentary work base is the analytical hinge.

Peripheral neuropathy claimants often have RFC restrictions that knock out sedentary work even when the listing does not hit. Cannot do fine manipulation more than occasionally on the dominant hand. Cannot operate foot controls. Needs to raise legs to relieve edema. Needs frequent unscheduled breaks. Needs assistive device for ambulation. Off task 15 percent or more of the workday from pain or medication effects. Two or more absences per month.

For claimants age 50 and over, the grid rules in 20 CFR Part 404 Subpart P Appendix 2 add weight. A claimant aged 55 with a high school education and unskilled past relevant work who is limited to sedentary RFC with non transferable skills grids out under Rule 201.14. Same claimant at age 50 grids out under Rule 201.12 if limited to sedentary work and unskilled. The grid does not require a listing hit. It requires a credible RFC that is less than light or sedentary.

State Specific Notes

If you are in Florida, the DDS office handles peripheral neuropathy files routinely because of the large diabetic and oncology populations. See the Florida state page for state specific timelines. Florida disability information.

If you are in California, the DDS prefers neurology NCS reports over primary care notes. Files without an objective electrodiagnostic study generally bounce at initial. California disability information.

If you are in Texas, DDS issues a high rate of one time consultative examinations on neuropathy files. Push back at reconsideration by ensuring the treating neurologist record is in the file. Texas disability information.

If you are in New York, DDS frequently approves diabetic neuropathy at initial if HbA1c documents poor control and a walker prescription is in the record. New York disability information.

If you are in Pennsylvania, DDS turnaround on neurology files in 2026 averages around 5 months at initial and 4 months at recon. Pennsylvania disability information.

Related Listing Deep Dives

• Listing 11.04 stroke and vascular insult to the brain
• Listing 11.06 Parkinsonian syndrome
• Listing 11.09 multiple sclerosis
• Listing 11.18 traumatic brain injury
• CRPS and RSDS under SSR 03-2p (medical equivalence to 11.14)
• POTS syndrome under listing 4.05 and 11.14 equivalence

Frequently Asked Questions